TIDMMEDG TIDMMEDU

RNS Number : 9526A

Medgenics Inc

05 April 2012

 
 Press Release   5 April 2012 
 

Medgenics, Inc.

("Medgenics" or the "Company")

Medgenics Announces Results of 2012 Annual Meeting of Stockholders

Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Company's Annual Meeting of Stockholders held yesterday were duly passed.

Each of the current directors of the Company, Dr. Eugene A. Bauer, Dr. Andrew L. Pearlman, Mr. Joel S. Kanter, Mr. Gary A. Brukardt, Dr. Stephen D. McMurray, Mr. Isaac Blech and Dr. Alastair Clemow, was re-elected to the Board of Directors to serve until the next Annual Meeting of Stockholders and until their successor is duly elected and qualified.

Stockholders also approved the amendment and restatement of the Company's Stock Incentive Plan, increasing the number of shares authorized to be issued under the plan and making certain other changes to the plan, and ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to serve as the Company's independent registered public accounting firm for the year ended December 31, 2012.

Final voting tallies are subject to certification by the Company's inspector of elections, and will be included in the Company's report to be filed with the Securities and Exchange Commission later this week.

About Medgenics

Medgenics is developing and commercializing a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, replacing their regular and costly injections of therapeutic proteins.

Medgenics has three long-acting protein therapy products in development based on this technology:

-- EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver erythropoietin for many months from a single administration, has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for six to more than 36 months;

-- INFRADURE(TM) (planning to commence a Phase I/II trial in Israel in 1H12 in hepatitis C) to produce a sustained therapeutic dose of interferon-alpha for use in the treatment of hepatitis;

-- HEMODURE(TM) is a sustained Factor VIII therapy for the prophylactic treatment of hemophilia, now in development.

Medgenics is focusing on the development and manufacturing of its innovative Biopumps(TM) and aims to bring them to market via strategic partnerships with major pharmaceutical and/or medical device companies.

In addition to treatments for anemia, hepatitis and hemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach $132 billion in 2013. Other potential applications for Biopumps include multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity and diabetes.

Forward-looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend, " "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

For further information, contact:

 
      Medgenics, Inc.                        Phone: +972 4 902 8900 
       Dr. Andrew L. Pearlman 
       andrew.pearlman@medgenics.com 
 
       LHA                                    Phone: 212-838-3777 
       Anne Marie Fields 
       afields@lhai.com 
       @LHA_IR_PR 
      Abchurch Communications                Phone: +44 207 398 7719 
       Adam Michael 
       Joanne Shears 
       Jamie Hooper 
       jamie.hooper@abchurch-group.com 
      Religare Capital Markets UK Ltd.       Phone: +44 207 444 0800 
       (NOMAD) 
       David Porter 
       Richard Thompson 
      SVS Securities plc (Joint Broker)      Phone: +44 207 638 5600 
       Alex Mattey 
       Ian Callaway 
      Nomura Code Securities (Joint Broker)  Phone: +44 207 776 1219 
       Jonathan Senior 
 

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGBSGDSRGGBGDU

Medgenics (LSE:MEDU)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Medgenics
Medgenics (LSE:MEDU)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Medgenics